Current Immunotherapeutic Strategies for Central Nervous System Tumors

Medina C. Kushen, Adam M. Sonabend, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Immunotherapy has emerged as a promising tool in the management of malignant central nervous system tumors. Despite improvement in patient survival, traditional approaches, which consist mostly of surgery, radiotherapy, and chemotherapy, have been largely unsuccessful in permanently controlling these aggressive tumors. Immunotherapeutic strategies offer not only a novel approach but also an advantage in a way other modalities have been failing. Specifically, the capabilities of the immune system to recognize altered cells while leaving normal cells intact offer tremendous advantage over the conventional therapeutic approaches. This article summarizes our current understanding of immunotherapeutic treatment modalities used in clinical trials for management of malignant central nervous system tumors.

Original languageEnglish (US)
Pages (from-to)987-1004
Number of pages18
JournalSurgical Oncology Clinics of North America
Volume16
Issue number4
DOIs
StatePublished - Oct 2007

Funding

This work was supported by a grant from the National Institutes of Neurological Disorders and Stroke (K08 NS046430 [ML]) and the Elsa U. Pardee Foundation (ML).

ASJC Scopus subject areas

  • Oncology
  • Surgery

Fingerprint

Dive into the research topics of 'Current Immunotherapeutic Strategies for Central Nervous System Tumors'. Together they form a unique fingerprint.

Cite this